Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02310568 · ClinicalTrials.gov registry record · Phase 2
POC Study in Partially Responsive Generalized Anxiety Disorder
A Phase 2 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 2
- Development phase
- 90
- Enrollment target
NCT02310568 is a Phase 2 study that was terminated before completion, run by Pfizer. The registered enrollment target is 90 participants.
The verdict
NCT02310568, a Phase 2 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 90 participants
- Enrollment target
Study Summary
This study aims to evaluate whether PF-06372865 is safe and effective in the treatment of sub-optimally controlled symptoms of generalized anxiety disorder during two 4-week treatment periods using a Sequential Parallel Comparison Design (SPCD). The study will use the Hamilton Anxiety Rating Scale (HAM-A) to measure change in symptoms from baseline for two doses of PF-06372865 compared to placebo.
Interventions
- DRUG PF-06372865.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2014-11 |
| Est. Completion | 2015-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02310568
The ClinicalTrials.gov registry entry for NCT02310568 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PF-06372865. is the first listed.
NCT02310568 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02310568 about?
NCT02310568 is a clinical study titled "POC Study in Partially Responsive Generalized Anxiety Disorder". This study aims to evaluate whether PF-06372865 is safe and effective in the treatment of sub-optimally controlled symptoms of generalized anxiety disorder during two 4-week treatment periods using a Sequential Parallel Comparison Design (SPCD). The study will use the Hamilton Anxiety Rating Scale (...
What is the current status of trial NCT02310568?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 90 participants. The study started on 2014-11. Estimated completion is 2015-10.
What interventions are being tested in trial NCT02310568?
The interventions under investigation include: PF-06372865. (DRUG).
Who is sponsoring clinical trial NCT02310568?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.